CD Tesis
analisis kesintasan pasien kanker payudara berdasarkan subtipe molekular kanker payudara
Introduction: Breast cancer is a heterogeneous disease with biological differences reflected in molecular subtypes, which influence patient survival outcomes. Survival data based on molecular subtypes in Riau Province have not previously been reported. This study aimed to analyze the association between molecular subtypes of breast cancer and patient survival at Arifin Achmad General Hospital, Pekanbaru.
Methods: This was a retrospective analytic study of breast cancer patients from 2014–2023. Data were obtained from medical records, with survival status verified through telephone follow-up or direct visits. Survival analysis was performed using the Kaplan–Meier method, and data were processed using SPSS version 26.0.
Results: A total of 1,796 patients met the inclusion criteria, with a mean age of 47.2 years. Most patients presented at a locally advanced stage (52.7%), and invasive ductal Carcinoma was the most common histopathology (69.2%). The molecular subType distribution was Luminal A 17.8%, Luminal B HER2− 16.6%, Luminal B HER2+ 25.3%, HER2 Type 26.3%, and triple-negative 14.0%. At the end of follow-up, 85.0% of patients were alive and 15.0% had died. Overall survival (OS) rates were 97.7% (1 year), 89.4% (2 years), 82.9% (3 years), 78.1% (4 years), and 79.7% (5 years). The highest 5-year OS was observed in Luminal B HER2− (84.1%), while the lowest was in triple-negative (73.6%).
Conclusion: Five-year breast cancer survival remains relatively favorable, with OS, progression-free survival, and disease-free survival indicating strong disease control and low recurrence rates. Immunohistochemistry subTypes play a cruIKal role, with Luminal B HER2− showing the best prognosis and triple-negative the worst, alongside other prognostic factors such as stage at diagnosis and presence of metastasis.
Keywords Breast cancer, Survival, Immunohistochemistry
Tidak tersedia versi lain